Tumour gene expression signature in primary melanoma predicts long-term outcomes.
Jönsson, Göran B
Wilmott, James S
Long, Georgina V
Springer Science and Business Media LLC
MetadataShow full item record
Garg, M., Couturier, D., Nsengimana, J., Fonseca, N. A., Wongchenko, M., Yan, Y., Lauss, M., et al. (2021). Tumour gene expression signature in primary melanoma predicts long-term outcomes.. Nat Commun, 12 (1) https://doi.org/10.1038/s41467-021-21207-2
Funder: University of Sydney Medical Foundation
Funder: Department of Health | National Health and Medical Research Council (NHMRC); doi: https://doi.org/10.13039/501100000925
Adjuvant systemic therapies are now routinely used following resection of stage III melanoma, however accurate prognostic information is needed to better stratify patients. We use differential expression analyses of primary tumours from 204 RNA-sequenced melanomas within a large adjuvant trial, identifying a 121 metastasis-associated gene signature. This signature strongly associated with progression-free (HR = 1.63, p = 5.24 × 10-5) and overall survival (HR = 1.61, p = 1.67 × 10-4), was validated in 175 regional lymph nodes metastasis as well as two externally ascertained datasets. The machine learning classification models trained using the signature genes performed significantly better in predicting metastases than models trained with clinical covariates (pAUROC = 7.03 × 10-4), or published prognostic signatures (pAUROC < 0.05). The signature score negatively correlated with measures of immune cell infiltration (ρ = -0.75, p < 2.2 × 10-16), with a higher score representing reduced lymphocyte infiltration and a higher 5-year risk of death in stage II melanoma. Our expression signature identifies melanoma patients at higher risk of metastases and warrants further evaluation in adjuvant clinical trials.
Databases, Genetic, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Machine Learning, Melanoma, Multivariate Analysis, Neoplasm Staging, Prognosis, Progression-Free Survival, Proportional Hazards Models, Reproducibility of Results, Time Factors, Treatment Outcome
External DOI: https://doi.org/10.1038/s41467-021-21207-2
This record's URL: https://www.repository.cam.ac.uk/handle/1810/337277
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: email@example.com